市場調查報告書

疾病分析:阿茲海默症

Disease Analysis: Alzheimer's disease

出版商 Datamonitor Healthcare 商品編碼 920044
出版日期 內容資訊 英文 91 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疾病分析:阿茲海默症 Disease Analysis: Alzheimer's disease
出版日期: 2019年11月19日內容資訊: 英文 91 Pages
簡介

2018年時,推測全球整體有7450萬名阿茲海默症患者,2027年其數將增加到1億0250萬人。

本報告提供全球阿茲海默症治療藥臨床實驗形勢與市場趨勢預測相關分析,疾病概要和流行病學的預測,目前主要治療藥 (已上市/開發中產品) 和臨床實驗的進展,目前未滿足需求和未來的市場機會,臨床實驗/市場前景相關專家的見解等資訊彙整,為您概述為以下內容。

概要

疾病的背景情況

  • 定義
  • 症狀
  • 風險要素
  • 患者的分類

治療方法

  • 膽鹼酯酶抑製劑:適合輕∼中度的阿茲海默症患者
  • Memantine:適合中∼重度的患者
  • 僅管欠缺功效,膽鹼酯酶抑制劑至今仍用於MCI(輕度認知障礙)的仿單標示外使用

流行病學

已上市醫藥品

開發平台醫藥品

近來的法規上的主要動向

成功的可能性

授權合約/資產收購交易

臨床實驗環境

  • 臨床試驗贊助者的分類:各狀況
  • 臨床試驗贊助者的分類:各相位
  • 目前的趨勢

醫藥品的評估模式

市場動態

未來趨勢

  • 非專利治療藥持續佔市場大半
  • aducanumab:混合的臨床實驗結果使未來模糊

共識的預測

近幾年的市場趨勢和分析師的見解

今後的市場主要動向

KOL (專家)的見解

  • 臨床端點的有意義的變更不可或缺
  • 非專利加入目前治療策略
  • 根據阿茲海默症的異質性,多樣的治療方法是必須的
  • 各個的治療範例

未滿足需求

  • 現在已認證的治療藥:最大也只有表現中度功效
  • 現狀的治療方法只有一時的效果,無法延長壽命
  • 不僅是認知方面、功能方面,阿茲海默症給行動方面也帶來不良影響

參考文獻

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0209750

KET TAKEAWAYS

Datamonitor Healthcare estimates that in 2018, there were 74.5 million prevalent cases of Alzheimer's disease in adults aged 65 years and older worldwide, and forecasts that number to increase to 102.5 million prevalent cases by

2027. The Alzheimer's disease market only includes four marketed products that are well established. The anticipation of growth has faded with the failure of immunotherapies to produce efficacious results on cognitive outcomes. The acetylcholinesterase class of drugs will continue to dominate the treatment of mild Alzheimer's disease, while NMDA receptor antagonist memantine is used primarily as an add-on or second-line therapy in more severe disease stages.

Biogen's unexpected decision to pursue FDA approval for its previously discontinued amyloid-targeting biologic aducanumab in Alzheimer's disease was met with skepticism given the surprising nature of the turnaround. It is by no means clear the drug will skate through the FDA approval process. Even if the drug is approved, it is uncertain how patients, physicians, and payers might weigh the potential cost of the drug against what could be viewed as incremental efficacy.

Trial data from the Phase III clinical trials for remaining beta amyloid-targeting antibodies BAN2401 and gantenerumab are expected in

2022. Other Phase III products targeting additional pathways have not produced sufficient clinical evidence to suggest a high likelihood of approval.

Generic erosion in Japan will contract the overall Alzheimer's disease market. This may be slightly offset by the increased prevalence owing to an aging population and advances in screening for the earliest phases of Alzheimer's disease that may lead to improved diagnosis rates.

The overall likelihood of approval of a Phase I Alzheimer's disease asset is 2.3%. The average probability an Alzheimer's drug advances from Phase III is only 15%, compared to 50% in the overall neurology space.

TABLE OF CONTENTS

CONTENTS

7 OVERVIEW

7 Latest key takeaways

8 DISEASE BACKGROUND

8 Definition

8 Symptoms

8 Risk factors

8 Patient segmentation

11 TREATMENT

11 Cholinesterase inhibitors are recommended for mild-to-moderate Alzheimer's disease

11 Memantine is reserved for moderate-to-severe disease

11 Despite lacking efficacy, cholinesterase inhibitors are still used off-label for MCI

12 EPIDEMIOLOGY

16 MARKETED DRUGS

19 PIPELINE DRUGS

40 KEY REGULATORY EVENTS

40 AARP-Funded Researchers Say Forget About Supplements To Improve Memory

40 Firms From Miami To Malaysia Warned On Disease Claims For Supplements

41 PROBABILITY OF SUCCESS

42 LICENSING AND ASSET ACQUISITION DEALS

42 Lilly And AC Immune Partner On A Small Molecule With Potential In Alzheimer's Combinations

42 Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors

43 CLINICAL TRIAL LANDSCAPE

44 Sponsors by status

45 Sponsors by phase

46 Recent events

49 DRUG ASSESSMENT MODEL

51 MARKET DYNAMICS

52 FUTURE TRENDS

52 Generic therapies will continue to dominate the Alzheimer's disease market

52 Mixed results from aducanumab cloud the outlook

54 CONSENSUS FORECAST

56 RECENT EVENTS AND ANALYST OPINION

56 GV-971 for Alzheimer's Disease

57 Aducanumab for Alzheimer's Disease (October 22, 2019)

59 Xanamem for Alzheimer's Disease (October 1, 2019)

61 AVP-786 for Alzheimer's Disease (September 27, 2019)

63 Elenbecestat for Alzheimer's Disease (September 13, 2019)

64 AADvac1 for Alzheimer's Disease (September 9, 2019)

65 Bryostatin for Alzheimer's Disease (September 9, 2019)

67 PTI-125 for Alzheimer's Disease (September 9, 2019)

69 GRF6019 for Alzheimer's Disease (Aug 5, 2019)

72 Azeliragon for Alzheimer's Disease (June 28, 2019)

73 Masitinib for Alzheimer's Disease (June 26, 2019)

74 Multiple Drugs for Alzheimer's Disease (June 25, 2019)

75 Xanamem for Alzheimer's Disease (May 7, 2019)

76 AVP-786 for Alzheimer's Disease (March 25, 2019)

78 Aducanumab for Alzheimer's Disease (March 21, 2019)

79 Crenezumab for Alzheimer's Disease (January 29, 2019)

81 UB-311 for Alzheimer's Disease (January 16, 2019)

83 Protein Degradation Program (Biogen/C4) for Alzheimer's Disease (January 4, 2019)

83 Lumateperone for Alzheimer's Disease (December 18, 2019)

85 KEY UPCOMING EVENTS

86 KEY OPINION LEADER INSIGHTS

86 Meaningful changes on clinical endpoints are essential

86 Generics are entrenched in current treatment strategies

86 Alzheimer's heterogeneity requires a diverse treatment approach

87 Individual treatment paradigms

88 UNMET NEEDS

88 Currently approved therapies display modest efficacy at best

88 Current treatments are only palliative and do not prolong survival

88 Beyond cognition and function, Alzheimer's disease also involves behavioral deficits

89 BIBLIOGRAPHY

89 Prescription Information

90 APPENDIX

LIST OF FIGURES

  • 15 Figure 1: Trends in prevalent cases of Alzheimer's disease, 2018-27
  • 19 Figure 2: Overview of pipeline drugs for Alzheimer's disease in the US
  • 20 Figure 3: Pipeline drugs for Alzheimer's disease, by company
  • 20 Figure 4: Pipeline drugs for Alzheimer's disease, by drug type
  • 21 Figure 5: Pipeline drugs for Alzheimer's disease, by classification
  • 41 Figure 6: Probability of success in the Alzheimer's disease pipeline
  • 43 Figure 7: Clinical trials in Alzheimer's disease
  • 43 Figure 8: Top 10 drugs for clinical trials in disease name
  • 44 Figure 9: Top 10 companies for clinical trials in disease name
  • 44 Figure 10: Trial locations in Alzheimer's disease
  • 45 Figure 11: Alzheimer's disease trials status
  • 46 Figure 12: Alzheimer's disease trials sponsors, by phase
  • 49 Figure 13: Datamonitor Healthcare's drug assessment summary for Alzheimer's disease
  • 51 Figure 14: Market dynamics in Alzheimer's disease
  • 52 Figure 15: Future trends in Alzheimer's disease
  • 59 Figure 16: Aducanumab for Alzheimer's Disease (October 22, 2019): Phase III - EMERGE (Early AD) , Phase III - ENGAGE (Early AD)
  • 61 Figure 17: Xanamem for Alzheimer's Disease (October 1, 2019): Phase I XanaHES (Elderly)
  • 65 Figure 18: AADvac1 for Alzheimer's Disease (September 9, 2019): Phase II - ADAMANT
  • 67 Figure 19: Bryostatin for Alzheimer's disease (September 9, 2019): Phase II - Confirmatory Study
  • 69 Figure 20: PTI-125 for Alzheimer's Disease (September 9, 2019): Phase IIa - Mild to Moderate AD
  • 85 Figure 21: Key upcoming events in Alzheimer's disease

LIST OF TABLES

  • 9 Table 1: Alzheimer's disease severity, by rating scale
  • 10 Table 2: FDA stages by disease attributes
  • 13 Table 3: Prevalent cases of Alzheimer's disease, 2018-27
  • 17 Table 4: Marketed drugs for Alzheimer's disease
  • 22 Table 5: Pipeline drugs for Alzheimer's disease in the US
  • 54 Table 6: Historical global sales, by drug ($m), 2014-18
  • 54 Table 7: Forecasted global sales, by drug ($m), 2019-23
  • 56 Table 8: GV-971 for Alzheimer's Disease (November 2, 2019)
  • 57 Table 9: Aducanumab for Alzheimer's Disease (October 22, 2019)
  • 59 Table 10: Xanamem for Alzheimer's Disease (October 1, 2019)
  • 62 Table 11: AVP-786 for Alzheimer's Disease (September 27, 2019)
  • 63 Table 12: Elenbecestat for Alzheimer's Disease (September 13, 2019)
  • 64 Table 13: AADvac1 for Alzheimer's Disease (September 9, 2019)
  • 66 Table 14: Bryostatin for Alzheimer's Disease (September 9, 2019)
  • 67 Table 15: PTI-125 for Alzheimer's Disease (September 9, 2019)
  • 70 Table 16: GRF6019 for Alzheimer's Disease (Aug 5, 2019)
  • 71 Table 17: CNP520 for Alzheimer's Disease (July 11, 2019)
  • 72 Table 18: Azeliragon for Alzheimer's Disease (June 28, 2019)
  • 73 Table 19: Masitinib for Alzheimer's Disease (June 26, 2019)
  • 74 Table 20: Multiple Drugs for Alzheimer's Disease (June 25, 2019)
  • 76 Table 21: Xanamem for Alzheimer's Disease (May 7, 2019)
  • 77 Table 22: AVP-786 for Alzheimer's Disease (March 25, 2019)
  • 78 Table 23: Aducanumab for Alzheimer's Disease (March 21, 2019)
  • 80 Table 24: Crenezumab for Alzheimer's Disease (January 29, 2019)
  • 81 Table 25: UB-311 for Alzheimer's Disease (January 16, 2019)
  • 83 Table 26: Protein Degradation Program (Biogen/C4) for Alzheimer's Disease (January 4, 2019)
  • 84 Table 27: Lumateperone for Alzheimer's Disease (December 18, 2019)
Back to Top